| 中文名称 |
SMND-309
|
| 中文别名 |
(2E)-2-[6-[(E)-2-羧基乙烯基]-2,3-二羟基苯基]-3-(3,4-二羟基苯基)丙烯酸
|
| 英文名称 |
SMND-309
|
| 英文别名 |
SMND-309;(E)-2-[6-[(E)-2-carboxyethenyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)prop-2-enoic acid;(2E)-2-{6-[(E)-2-carboxyvinyl]-2,3-dihydroxyphenyl}-3-(3,4-dihydroxyphenyl) propenoic acid;(E)-2-(6-((E)-2-carboxyvinyl)-2,3-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)acrylic acid;CS-0559;HY-13056;salvianolic acid E;SMND 309;(2E)-2-[6-[(E)-2-Carboxyvinyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)acrylic acid
|
| Cas No. |
1065559-56-9
|
| 分子式 |
C18H14O8
|
| 分子量 |
358.30
|
| 包装储存 |
Powder -20°C 3 years;4°C 2 years
|
| 详情描述 |
SMND-309 是丹酚酸 B 的代谢产物,在神经元和永久性大脑动脉闭塞大鼠中具有保护神经的作用。
|
| 产品详情 |
SMND-309 是丹酚酸 B 的代谢产物,在神经元和永久性大脑动脉闭塞大鼠中具有保护神经的作用。
|
| 生物活性 |
SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
|
| 性状 |
Solid
|
| 体内研究(In Vivo) |
SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years;4°C 2 years
|
| 参考文献 |
[1]. Hou J, Tian J, Jiang W, Gao Y, Fu F.
Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis.
Eur J Pharmacol. 2011 Jan 10;650(1):390-5.[2]. Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J.
Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats.
Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.
|
| 溶解度数据 |
In Vitro: DMSO : ≥ 3.7 mg/mL (10.33 mM)配制储备液
|
[1]. Hou J, Tian J, Jiang W, Gao Y, Fu F.
Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis.
Eur J Pharmacol. 2011 Jan 10;650(1):390-5.[2]. Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J.
Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats.
Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。